|
Gene: TCF20 |
Gene summary for TCF20 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TCF20 | Gene ID | 6942 |
Gene name | transcription factor 20 | |
Gene Alias | AR1 | |
Cytomap | 22q13.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UGU0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6942 | TCF20 | CCI_1 | Human | Cervix | CC | 6.05e-09 | 6.63e-01 | 0.528 |
6942 | TCF20 | CCI_2 | Human | Cervix | CC | 1.01e-08 | 6.95e-01 | 0.5249 |
6942 | TCF20 | CCI_3 | Human | Cervix | CC | 6.08e-19 | 1.05e+00 | 0.516 |
6942 | TCF20 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.41e-03 | 5.03e-01 | -0.059 |
6942 | TCF20 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 9.96e-03 | 5.57e-01 | 0.3859 |
6942 | TCF20 | A001-C-207 | Human | Colorectum | FAP | 8.20e-04 | -9.44e-02 | 0.1278 |
6942 | TCF20 | A015-C-203 | Human | Colorectum | FAP | 1.62e-28 | -2.46e-01 | -0.1294 |
6942 | TCF20 | A015-C-204 | Human | Colorectum | FAP | 2.13e-07 | -1.99e-01 | -0.0228 |
6942 | TCF20 | A014-C-040 | Human | Colorectum | FAP | 9.71e-07 | -4.71e-01 | -0.1184 |
6942 | TCF20 | A002-C-201 | Human | Colorectum | FAP | 2.44e-12 | -2.26e-01 | 0.0324 |
6942 | TCF20 | A002-C-203 | Human | Colorectum | FAP | 3.78e-04 | 1.16e-01 | 0.2786 |
6942 | TCF20 | A001-C-119 | Human | Colorectum | FAP | 1.05e-06 | -1.73e-01 | -0.1557 |
6942 | TCF20 | A001-C-108 | Human | Colorectum | FAP | 3.61e-16 | -2.02e-01 | -0.0272 |
6942 | TCF20 | A002-C-205 | Human | Colorectum | FAP | 1.05e-23 | -1.86e-01 | -0.1236 |
6942 | TCF20 | A001-C-104 | Human | Colorectum | FAP | 3.17e-02 | -2.72e-02 | 0.0184 |
6942 | TCF20 | A015-C-005 | Human | Colorectum | FAP | 1.06e-03 | -1.31e-01 | -0.0336 |
6942 | TCF20 | A015-C-006 | Human | Colorectum | FAP | 8.20e-16 | -2.56e-01 | -0.0994 |
6942 | TCF20 | A015-C-106 | Human | Colorectum | FAP | 1.08e-10 | -1.33e-01 | -0.0511 |
6942 | TCF20 | A002-C-114 | Human | Colorectum | FAP | 8.93e-21 | -4.33e-01 | -0.1561 |
6942 | TCF20 | A015-C-104 | Human | Colorectum | FAP | 3.14e-33 | -3.65e-01 | -0.1899 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | |
Lung | IAC | |
Lung | AIS | |
Lung | AAH | |
Lung | MIAC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TCF20 | SNV | Missense_Mutation | novel | c.3929C>G | p.Ser1310Cys | p.S1310C | Q9UGU0 | protein_coding | deleterious(0.02) | benign(0.387) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
TCF20 | SNV | Missense_Mutation | rs763864152 | c.3229N>A | p.Ala1077Thr | p.A1077T | Q9UGU0 | protein_coding | tolerated_low_confidence(0.49) | benign(0) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TCF20 | SNV | Missense_Mutation | c.431C>G | p.Ser144Cys | p.S144C | Q9UGU0 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TCF20 | SNV | Missense_Mutation | rs754031239 | c.2102N>T | p.Ser701Phe | p.S701F | Q9UGU0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TCF20 | SNV | Missense_Mutation | rs760478206 | c.2116N>T | p.Arg706Cys | p.R706C | Q9UGU0 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.854) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
TCF20 | SNV | Missense_Mutation | c.5866C>A | p.Gln1956Lys | p.Q1956K | Q9UGU0 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.9) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD | |
TCF20 | SNV | Missense_Mutation | novel | c.3941G>A | p.Arg1314Lys | p.R1314K | Q9UGU0 | protein_coding | tolerated(0.6) | benign(0.104) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
TCF20 | SNV | Missense_Mutation | c.4127N>A | p.Gly1376Glu | p.G1376E | Q9UGU0 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
TCF20 | SNV | Missense_Mutation | novel | c.2063C>G | p.Ala688Gly | p.A688G | Q9UGU0 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
TCF20 | SNV | Missense_Mutation | novel | c.1826C>G | p.Ser609Cys | p.S609C | Q9UGU0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.921) | TCGA-GM-A2DM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |